Clinical Trials Logo

Inherited Disease clinical trials

View clinical trials related to Inherited Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05386134 Recruiting - Genetic Disease Clinical Trials

Adaptive Optics Retinal Imaging in Inherited and Acquired Retinal Disorders

Start date: June 13, 2022
Phase:
Study type: Observational

This is a Prospective Observational study. The aim of the study is to understand the underlying photoreceptor, retinal pigment epithelium or retinal vascular aberrations in inherited and acquired retinal disorders. The study would use adaptive optics (AO) technology to assist in-vivo visualization of these retinal structures and ascertain changes from normal. Further, by using the AO imaging in patients before and after treatments, this study aims to better understand the effect of various interventions and develop AO as an outcome measure in various retinal disorders.

NCT ID: NCT04880356 Recruiting - Metabolic Disease Clinical Trials

Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.

Start date: March 1, 2021
Phase:
Study type: Observational

General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in adulthood through the systematic longitudinal collection of clinical, laboratory and instrumental data.

NCT ID: NCT03589079 Recruiting - Genetic Disorder Clinical Trials

Delineation of Novel Monogenic Disorders in the United Arab Emirates Population

Start date: January 1, 2018
Phase:
Study type: Observational

The study aims to identify novel monogenic phenotypes from specific pedigrees and discover the underlying causal genetic variant using genetic sequencing (Sanger and/or Next Generation Sequencing - Panel/WES/WGS) methodologies in families across the United Arab Emirates (UAE).

NCT ID: NCT03568630 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Blood Markers of Early Pancreas Cancer

Start date: July 26, 2018
Phase:
Study type: Observational

Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.